Skip to content

A randomized, open-label, parallel-group study to evaluate the efficacy of dry chemical mopping in adults with mild to moderate atopic dermatitis.

A randomized, open-label, parallel-group study to evaluate the efficacy of dry chemical mopping in adults with mild to moderate atopic dermatitis. - Cleaning Research

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000045727
Enrollment
42
Registered
2021-10-12
Start date
2023-06-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis of mild to moderate severity

Interventions

Floor mop is used for 24 weeks Vacuum cleaner is used for 24 weeks

Sponsors

Mie University, Graduate School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Men and women who are between 20 and 80 years old at the time of obtaining consent. 2) Those who are in charge of cleaning their homes, have a habit of cleaning with an electric vacuum cleaner, and are able to clean their homes early every morning. 3) Those who are able to come to the examination according to the set schedule. 4) Patients with mild to moderate atopic dermatitis who have stable symptoms (no change in medication, regardless of whether or not the patient has been to the hospital (to prevent changes in skin characteristics)). Patients with chronic diseases such as internal medicine that require regular visits to the hospital and treatment with oral medication will be included in the selection criteria, and changes in medication will be possible, although reporting will be required. 5) Those who have received sufficient explanation and written consent of their own free will to participate in this clinical study.

Exclusion criteria

Exclusion criteria: 1) Persons who are active during the night and sleep during the day 2) Persons who are judged by the principal investigator or sub-investigator to be inappropriate as research subjects.

Design outcomes

Primary

MeasureTime frame
Group differences in the change in IgE between the initial value and the 24th week of use.

Secondary

MeasureTime frame
The initial values for View Allergy39 will be the values on the day of the measurement selected for the study. View Allergy39 (only 18 items related to inhalation), TARC, eosinophils, and visual examination score at the dermatologist interview.

Countries

Japan

Contacts

Public ContactKoji Umeda

KSK Laboratories,Inc. representative

info@ksk-lab.co.jp059-253-8091

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026